Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 3/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | CASP7 | P55210 | 3/20 | 0.54 |
| ▸ | CASP1 | P29466 | 2/20 | 0.54 |
| ▸ | CASP9 | P55211 | 2/20 | 0.54 |
| ▸ | CTSD | P07339 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 3/20 | 0.51 |
| ▸ | MME | P08473 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485154 | 1.00 | CASP3 (0.62) | CASP3CA2CA5ACTSKCTSB | |
| SCHEMBL22811283 | 1.00 | CASP3 (0.62) | CASP3CA2CA5ACTSKCTSB | |
| SCHEMBL22209445 | 0.91 | CASP3 (0.55) | CASP3CA2CA5ACTSKCTSB | |
| SCHEMBL14479029 | 0.91 | CASP3 (0.55) | CASP3CA2CA5ACTSKCTSB | |
| SCHEMBL10985362 | 0.91 | CTSS (0.53) | CASP3CTSKCTSBCTSLCTSS | |
| SCHEMBL25287172 | 0.90 | ECE1 (0.61) | CASP3CTSKCTSBCTSLCTSS | |
| SCHEMBL3058668 | 0.90 | ECE1 (0.61) | CASP3CTSKCTSBCTSLCTSS | |
| SCHEMBL14148466 | 0.89 | CTSK (0.65) | CASP3CTSKCTSBCTSLCTSS | |
| SCHEMBL25285647 | 0.89 | CTSK (0.65) | CASP3CTSKCTSBCTSLCTSS | |
| SCHEMBL25251125 | 0.89 | CTSK (0.65) | CASP3CTSKCTSBCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10711036-B2 | MALT1 inhibitors and uses thereof | CORNELL UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180251489-A1 | MALT1 INHIBITORS AND USES THEREOF | Cornell University Cornell Center for Technology Enterprise & Commercialization (CCTEC) (US) | 2018-09-06 | — | — | US | disclosed |
| US-20100035946-A1 | INDOLINE ANTI-CANCER AGENTS | JOYANT PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100022607-A1 | DIAZONAMIDE ANALOGS | JOYANT PHARMACEUTICALS, INC. | 2010-01-28 | — | — | US | disclosed |
| WO-2009143485-A1 | DIAZONAMIDE ANALOGS | JOYANT PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009134938-A1 | INDOLINE ANTI-CANCER AGENTS | JOYANT PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009086170-A1 | DIAZONAMIDE ANALOGS WITH IMPROVED SOLUBILITY | JOYANT PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163446-A1 | DIAZONAMIDE ANALOGS WITH IMPROVED SOLUBILITY | JOYANT PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163446-A1 | DIAZONAMIDE ANALOGS WITH IMPROVED SOLUBILITY | JOYANT PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090005572-A1 | METHODS FOR PREPARING DIAZONAMIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| US-20090005572-A1 | METHODS FOR PREPARING DIAZONAMIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-01 | — | — | US | disclosed |
| WO-2008154441-A1 | METHODS FOR PREPARING DIAZONAMIDES | JOYANT PHARMACEUTICALS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005572-A1 | METHODS FOR PREPARING DIAZONAMIDES | CBR3, PPOX, POR | CASP3 2015/4885CA2 1746/4885CA5A 573/4885 |
| US-20090163446-A1 | DIAZONAMIDE ANALOGS WITH IMPROVED SOLUBILITY | PKD1, PKD2, GLS | CASP3 1545/4885CA2 1203/4885CA5A 450/4885 |
| US-20180251489-A1 | MALT1 INHIBITORS AND USES THEREOF | MALT1, BCL3, BCL6 | CASP3 1784/4885CA2 3705/4885CA5A 2759/4885 |
| US-10711036-B2 | MALT1 inhibitors and uses thereof | MALT1, BCL3, BCL6 | CASP3 1973/4885CA2 3744/4885CA5A 2772/4885 |
| US-20100035946-A1 | INDOLINE ANTI-CANCER AGENTS | MKI67, CCNB2, CCNI | CASP3 576/4885CA2 2884/4885CA5A 1208/4885 |
| US-20100022607-A1 | DIAZONAMIDE ANALOGS | BUB1B, BOD1L1, CDK14 | CASP3 878/4885CA2 2595/4885CA5A 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.